Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Ovarian Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Glioma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Fluorouracil 98Oxaliplatin 94Leucovorin 86Irinotecan 70Gemcitabine 66Bevacizumab 62Capecitabine 60Cetuximab 42pembrolizumab 37Cisplatin 30Nivolumab 25Drug Therapy 25130-nm albumin-bound paclitaxel 22Specimen Handling 20Folfox protocol 20Panitumumab 19Paclitaxel 19Magnetic Resonance Spectroscopy 18Albumin-Bound Paclitaxel 17Biopsy 16IFL protocol 15Floxuridine 15Docetaxel 15Cyclophosphamide 15Sorafenib 14regorafenib 12Erlotinib Hydrochloride 12aflibercept 11Radiofrequency Ablation 11fludarabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × sapanisertib × Gastrointestinal × Clear all
NCT02159989 2025-10-20

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
83 enrolled 21 charts
GastrointestinalGynecologic

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡